1.
Leuk Lymphoma
; 29(3-4): 329-38, 1998 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-9684930
RESUMO
We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted the manufacturing of a highly purified clinical-grade B43-Genistein preparation. In clonogenic assays, B43-Genistein elicited selective and potent cytotoxicity against CD19 antigen positive human leukemia cells. To our knowledge, this work represents the first effort of producing a clinical-grade genistein immunoconjugate for treatment of B-lineage leukemia and lymphoma.
Assuntos
Anticorpos Monoclonais , Antineoplásicos , Genisteína , Imunoconjugados/química , Antineoplásicos/uso terapêutico , Genisteína/uso terapêutico , Humanos , Imunoconjugados/uso terapêutico , Leucemia/terapia , Linfoma/terapia , Células Tumorais Cultivadas/efeitos dos fármacos
2.
Bull Soc Ophtalmol Fr
; 78(8-9): 555-9, 1978.
Artigo
em Francês
| MEDLINE
| ID: mdl-751751